

COVID-19 Death and BCG Vaccination



Viroj Wiwanitkit, M.D.

Department of Community Medicine, Dr DY Patil University, Pune, India

Dear Editor, I would like to share ideas on the publication "COVID-19 Death and BCG Vaccination Programs Worldwide"¹. Jirjees et al. concluded that "it can be concluded that the early establishment of BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases." The interrelationship between coronavirus disease 2019 (COVID-19) and tuberculosis is interesting. Whether bacillus Calmette-Guerin (BCG) can help prevent the infection and mortality due to COVID-19 is an issue to be further studied. From an early report from Indochina, the co-existence between both COVID-19 and tuberculosis is possible². In that area, Thailand, the BCG is mandatory and more than 99% coverage rate is officially declared. However, there is still a problem of COVID-19 infection and death. Focusing on infected case and death case, it appeared that all cases had BCG vaccination. There is no association between BCG vaccination history and COVID-19 infection or COVID-19 death. In fact, there is also no identified biological process of BCG that can link to the pathogenesis process of severe acute respiratory syndrome coronavirus 2. Therefore, it seems that it might not confirm that BCG vaccination can affect the incidence of COVID-19 infection and death.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

- 1. Jirjees FJ, Dallal Bashi YH, Al-Obaidi HJ. COVID-19 death and BCG vaccination programs worldwide. Tuberc Respir Dis 2021;84:13-21.
- 2. Yasri S, Wiwanitkit V. Tuberculosis and novel Wuhan coronavirus infection: pathological interrelationship. Indian J Tuberc 2020;67:264.

Address for correspondence: Viroj Wiwanitkit, M.D.

Department of Community Medicine, Dr DY Patil University, Sant Tukaram Nagar, Pimpi Colony, Pune, Maharashtra 411018, India

Phone: 91-20-27805100, **Fax:** 91-20-27805100

E-mail: wviroj@yahoo.com Received: Sep. 17, 2020 Revised: Sep. 30, 2020 Accepted: Oct. 7, 2020 Published online: Oct. 8, 2020

©It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).



Copyright © 2021

The Korean Academy of Tuberculosis and Respiratory Diseases.